A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia.
about
DNA Methylation and Chromatin Remodeling: The Blueprint of Cancer EpigeneticsEvolving Therapeutic Strategies for the Classic Philadelphia-Negative Myeloproliferative NeoplasmsNew Therapeutic Approaches in Polycythemia VeraManagement of polycythaemia vera: a critical review of current data.Epigenetics in diagnosis, prognostic assessment and treatment of cancer: an update.The Bone Marrow-Mediated Protection of Myeloproliferative Neoplastic Cells to Vorinostat and Ruxolitinib Relies on the Activation of JNK and PI3K Signalling Pathways.Novel and emerging therapies for the treatment of polycythemia veraFrom leeches to personalized medicine: evolving concepts in the management of polycythemia vera.Polycythemia vera disease burden: contributing factors, impact on quality of life, and emerging treatment options.Ruxolitinib for the treatment of patients with polycythemia vera.How we diagnose and treat essential thrombocythaemia.Investigational histone deacetylase inhibitors (HDACi) in myeloproliferative neoplasms.Minimal residual disease after long-term interferon-alpha2 treatment: a report on hematological, molecular and histomorphological response patterns in 10 patients with essential thrombocythemia and polycythemia vera.Epigenetic changes in myelofibrosis: Distinct methylation changes in the myeloid compartments and in cases with ASXL1 mutationsA phase II study of vorinostat (MK-0683) in patients with primary myelofibrosis and post-polycythemia vera myelofibrosis.A physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model of the histone deacetylase (HDAC) inhibitor vorinostat for pediatric and adult patients and its application for dose specification.Developmental Therapeutics in Myeloproliferative Neoplasms.
P2860
Q26749421-CC1097CE-9870-4935-949B-CB7A29A9E231Q26766319-3E214EFB-829C-4835-AB43-3D04DA19EF69Q26795677-984D833D-D989-41C9-82E5-E7E1D7D12D00Q31009757-666BD3BC-0F70-4F7E-AFD9-59151B3F9B2DQ35726371-A1D8AB70-A9F1-417F-8F72-598EDADDF307Q35856790-34DF614D-3F54-403C-8BB6-C772903C5BE8Q37069633-B0E80FD6-6AB7-445A-BD73-81F49201EEDAQ37555790-55431381-1158-46B9-84FF-18EE8CB7F4B6Q38255717-0AF25031-45CC-4A6A-8452-2A7A44F90952Q38484321-24239294-B600-4C27-BF1D-69C63D1D2E73Q38606595-51DA7746-55EF-4FAA-90FF-92C5D19A7332Q38984578-AE4C464E-39FF-4DB6-A65D-1968D47ADC20Q40959669-3B5E6616-3251-49D0-A7AF-2A4047D76A30Q42339242-01581CDC-9131-4B55-A4D9-BDCE30109B29Q42551329-EF1715A4-35CC-407F-9EDB-9DCD789AC7ACQ47843990-3D91B911-BDBB-40A0-97F7-44E2826F3DF2Q48008083-AED53E59-A6CE-4345-BB16-2C8A05494F65
P2860
A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
A phase II study of vorinostat ...... nd essential thrombocythaemia.
@en
A phase II study of vorinostat
@nl
type
label
A phase II study of vorinostat ...... nd essential thrombocythaemia.
@en
A phase II study of vorinostat
@nl
prefLabel
A phase II study of vorinostat ...... nd essential thrombocythaemia.
@en
A phase II study of vorinostat
@nl
P2093
P2860
P356
P1476
A phase II study of vorinostat ...... and essential thrombocythaemia
@en
P2093
Bjørn Andreasson
Christen L Andersen
Claire Harrison
David Bareford
Elisabeth Ejerblad
Erik Ahlstrand
Eva Löfvenberg
Hanne Vestergaard
Herdis Larsen
Jan Samuelsson
P2860
P304
P356
10.1111/BJH.12416
P407
P577
2013-06-11T00:00:00Z